6-Feb-2026
No headlines found.
Ryoncil Net Revenues Increase for the Quarter to US$30M
Globe Newswire (Wed, 28-Jan 6:54 PM ET)
Globe Newswire (Mon, 26-Jan 6:45 PM ET)
Globe Newswire (Sun, 18-Jan 7:01 PM ET)
Ryoncil Sales Increase 60% in December Quarter to US$35.1M
Globe Newswire (Thu, 8-Jan 6:46 PM ET)
Mesoblast Announces Changes to Board of Directors' Leadership Roles
Globe Newswire (Thu, 1-Jan 6:02 PM ET)
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
Globe Newswire (Mon, 29-Dec 6:57 PM ET)
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
PRNewswire (Tue, 16-Dec 11:53 AM ET)
Globe Newswire (Thu, 11-Dec 6:22 PM ET)
Mesoblast Participation at Piper Sandler Conference
Globe Newswire (Wed, 3-Dec 6:10 PM ET)
Globe Newswire (Mon, 24-Nov 6:39 PM ET)
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Mesoblast Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol MESO.
As of February 6, 2026, MESO stock price declined to $15.95 with 276,471 million shares trading.
MESO has a beta of 1.71, meaning it tends to be more sensitive to market movements. MESO has a correlation of 0.17 to the broad based SPY ETF.
MESO has a market cap of $2.06 billion. This is considered a Mid Cap stock.
Last quarter Mesoblast Limited - American Depositary Shares reported $17 million in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-26 million and exceeded earnings estimates by $.63.
In the last 3 years, MESO traded as high as $22.00 and as low as $1.61.
The top ETF exchange traded funds that MESO belongs to (by Net Assets): IBB, APIE, IBBQ, BIB.
MESO has underperformed the market in the last year with a price return of -14.7% while the SPY ETF gained +15.1%. However, in the short term, MESO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +6.8% vs +3.3% return in SPY. But in the last 2 weeks, MESO shares have been beat by the market, returning -13.2% compared to an SPY return of +0.2%.
MESO support price is $15.54 and resistance is $16.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MESO shares will trade within this expected range on the day.